Stock Scorecard



Stock Summary for Foghorn Therapeutics Inc (FHTX) - $4.40 as of 5/13/2025 5:56:43 PM EST

Total Score

12 out of 30

Safety Score

25 out of 100

Currently on the following lists
Small Cap Stock List
Tim's Recommendation
Possible Buy

Growth List Algorithm Criteria for FHTX

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for FHTX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for FHTX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for FHTX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for FHTX (25 out of 100)

Stock Price Rating (Max of 10) 3
Historical Stock Price Rating (Max of 10) 7
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 4
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for FHTX

Sutro Biopharma, Inc. ( STRO ) Reports Q1 Loss, Tops Revenue Estimates 5/8/2025 9:50:00 PM
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference - Foghorn Therapeutics ( NASDAQ:FHTX ) 5/5/2025 11:00:00 AM
Amicus Therapeutics ( FOLD ) Q1 Earnings and Revenues Lag Estimates 5/1/2025 12:15:00 PM
This PayPal Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday - General Mills ( NYSE:GIS ) , Foghorn Therapeutics ( NASDAQ:FHTX ) 4/23/2025 1:19:00 PM
Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting - Foghorn Therapeutics ( NASDAQ:FHTX ) 4/15/2025 11:00:00 AM
Flagship Pioneering Announces Agreement Between Pioneering Medicines and Pfizer to Discover Potential Novel, Selective Inhibitors for Autoimmune Disease - Foghorn Therapeutics ( NASDAQ:FHTX ) , Moderna ( NASDAQ:MRNA ) 4/1/2025 12:00:00 PM
Why PVH Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - bioAffinity Technologies ( NASDAQ:BIAF ) , Cambium Networks ( NASDAQ:CMBM ) 4/1/2025 9:30:00 AM
Why PVH Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - bioAffinity Technologies ( NASDAQ:BIAF ) , Cambium Networks ( NASDAQ:CMBM ) 4/1/2025 9:29:00 AM
Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting - Foghorn Therapeutics ( NASDAQ:FHTX ) 3/25/2025 8:35:00 PM
Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting 3/25/2025 8:35:00 PM

Financial Details for FHTX

Company Overview

Ticker FHTX
Company Name Foghorn Therapeutics Inc
Country USA
Description Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs that target genetically determined dependencies within the chromatin regulatory system. The company is headquartered in Cambridge, Massachusetts.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 4.40
Price 4 Years Ago 22.87
Last Day Price Updated 5/13/2025 5:56:43 PM EST
Last Day Volume 108,665
Average Daily Volume 137,801
52-Week High 10.25
52-Week Low 2.94
Last Price to 52 Week Low 49.66%

Valuation Measures

Trailing PE N/A
Industry PE 28.89
Sector PE 49.07
5-Year Average PE -3.30
Free Cash Flow Ratio 4.40
Industry Free Cash Flow Ratio 18.95
Sector Free Cash Flow Ratio 31.66
Current Ratio Most Recent Quarter 3.73
Total Cash Per Share 1.00
Book Value Per Share Most Recent Quarter -0.82
Price to Book Ratio 10.71
Industry Price to Book Ratio 38.10
Sector Price to Book Ratio 30.44
Price to Sales Ratio Twelve Trailing Months 10.35
Industry Price to Sales Ratio Twelve Trailing Months 93.45
Sector Price to Sales Ratio Twelve Trailing Months 25.43
Analyst Buy Ratings 5
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 55,721,000
Market Capitalization 245,172,400
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 11.99%
Reported EPS 12 Trailing Months -1.58
Reported EPS Past Year 0.00
Reported EPS Prior Year -1.65
Net Income Twelve Trailing Months -86,620,000
Net Income Past Year -86,620,000
Net Income Prior Year -98,426,000
Quarterly Revenue Growth YOY -50.50%
5-Year Revenue Growth 339.99%
Operating Margin Twelve Trailing Months -841.00%

Balance Sheet

Total Cash Most Recent Quarter 55,454,000
Total Cash Past Year 55,454,000
Total Cash Prior Year 80,336,000
Net Cash Position Most Recent Quarter 35,540,000
Net Cash Position Past Year 35,800,000
Long Term Debt Past Year 19,654,000
Long Term Debt Prior Year 19,654,000
Total Debt Most Recent Quarter 19,914,000
Equity to Debt Ratio Past Year 0.00
Equity to Debt Ratio Most Recent Quarter 0.00
Total Stockholder Equity Past Year -45,528,000
Total Stockholder Equity Prior Year -77,190,000
Total Stockholder Equity Most Recent Quarter -45,528,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -101,312,000
Free Cash Flow Per Share Twelve Trailing Months -1.82
Free Cash Flow Past Year -101,312,000
Free Cash Flow Prior Year -119,330,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating None

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.09
MACD Signal 0.05
20-Day Bollinger Lower Band 3.13
20-Day Bollinger Middle Band 4.35
20-Day Bollinger Upper Band 5.58
Beta 3.13
RSI 56.89
50-Day SMA 6.01
150-Day SMA 6.89
200-Day SMA 8.50

System

Modified 5/12/2025 11:54:48 PM EST